In January 2026, Pat McGrath — the woman Vogue once called “the most influential makeup artist in the world” — watched her billion-dollar beauty empire file for Chapter 11 bankruptcy. Pat McGrath Labs, valued at $1 billion in 2018 after a landmark investment from Eurazeo Brands, had seen sales collapse to $29.6 million in 2025, down more than 50% from $61.1 million the year before. Sienna Investment Managers, one of the brand’s backers, had already marked down its stake by 88% — implying a valuation closer to $174 million.
She wasn’t alone. Within weeks, Gwen Stefani’s Gxve Beauty quietly disappeared from Sephora shelves with no public statement. Drew Barrymore’s Flower Beauty shut down after 13 years. Cover FX and Mally Beauty — both owned by AS Beauty Group, founded by the original e.l.f. Cosmetics team — announced permanent closures on the same day.
Five brands gone in a matter of months. The celebrity beauty model isn’t just struggling — it’s in a full-blown correction. But here’s the strange part: while these brands were dying, Rare Beauty was being valued at $2.7 billion, and Hailey Bieber sold Rhode to e.l.f. Beauty for $1 billion after just three years. Same industry. Same timeframe. Opposite outcomes.
The difference between the winners and the casualties isn’t fame. It’s something more fundamental — and it carries lessons that go well beyond the beauty aisle.
The 2026 Celebrity Beauty Graveyard
The scale of the collapse is hard to overstate. Pat McGrath Labs went from cultural phenomenon to court-supervised restructuring in under eight years. The brand launched in 2015 with a single gold pigment kit that sold out in minutes. By 2018, it had a unicorn valuation and Dame Pat McGrath was the richest self-made makeup artist on the planet.
But the cracks were forming early. When Eurazeo invested at that $1 billion valuation, Women’s Wear Daily reported expected sales of $60 million for the year — which was actually $20 million higher than reality. Eurazeo withdrew funding entirely by 2021. By January 2026, GDA Luma Capital Management stepped in with $30 million in emergency financing, taking a controlling equity stake. McGrath moved from CEO to Chief Creative Officer of the brand she built.
Gxve Beauty’s death was quieter but equally telling. Launched in 2022 through Sephora with VC backing from New Theory Ventures — the same firm behind Rare Beauty — the brand leaned heavily on Stefani’s rockstar image and signature red lip. Four years later, the website went dark, social media accounts vanished, and Sephora confirmed it stopped carrying the line at the start of 2026. No farewell tour. No explanation.
Flower Beauty’s exit had more gravity. Drew Barrymore’s mass-market line launched in 2012, making it one of the original celebrity beauty brands — years before Fenty or Rare Beauty existed. It was incubated by Maesa and distributed through Walmart, CVS, and Ulta. But when Maesa decided to exit color cosmetics entirely in 2025, Flower Beauty was collateral damage. Thirteen years of shelf space, erased.
Then came Cover FX and Mally Beauty, shut down on January 22, 2026, by parent company AS Beauty Group. Both brands cited tariffs and a shifting global market, but the real story was simpler: AS Beauty wanted to concentrate resources on brands with growth potential. Cover FX and Mally didn’t make the cut.
Why Do Celebrity Beauty Brands Fail?
The easy answer is “market saturation,” and it’s not wrong. (We’ve written before about what makes celebrity brands irresistible — but irresistible doesn’t mean invincible.) Seven celebrity beauty brands launched in 2020. Eleven in 2021. Twelve in 2022. By 2024, consumers had more celebrity-branded lipsticks available than they could test in a lifetime, and the novelty had worn thin.
But saturation alone doesn’t explain why some brands thrived while others drowned in the same crowded market. The actual failure pattern is more specific, and it repeats across nearly every casualty.
The name-as-strategy problem. Most failed celebrity brands treated the founder’s fame as a substitute for product-market fit. The pitch to investors was straightforward: big name plus beauty category equals money. The problem is that celebrity awareness gets someone to look at the product once. It doesn’t get them to buy it a second time. As one industry analyst told The Drum, consumers were skeptical about whether celebrities actually used the products they pushed — and the market was oversaturated with launches that felt interchangeable.
Misaligned capital structures. Pat McGrath Labs is the clearest example. The $1 billion valuation in 2018 was based on projected sales that exceeded actual revenue by roughly $20 million. That gap between valuation and reality created an unsustainable capital structure — the brand needed to grow into a number it was never actually hitting. When growth stalled, the debt became a trap. McGrath herself described the filing as the result of “an unsustainable capital structure, accumulated legacy liabilities, and liquidity constraints.”
Corporate parent risk. Flower Beauty and Gxve illustrate a different failure mode: dependency on a single distribution partner or parent company. When Maesa exited color cosmetics, Flower Beauty had no independent infrastructure to survive. When Sephora dropped Gxve, there was no DTC business or alternative retailer to fall back on. These brands were tenants, not owners — and when the landlord left, they had nowhere to go.
Lack of community. This is the factor that separates winners from losers most reliably. The brands that died had customers. The brands that survived have communities. There’s a critical difference. Customers buy a product because of who made it. Communities buy because of what the brand represents, how it makes them feel, and the relationship they have with the founder and each other.
What Rare Beauty and Rhode Did Differently
Rare Beauty launched in September 2020 — during a pandemic, into a saturated market — and is now valued at $2.7 billion. Rhode launched in June 2022 with ten products and sold to e.l.f. Beauty for $1 billion in May 2025 after just three years. These aren’t exceptions to the celebrity beauty collapse. They’re the proof that the collapse is about execution, not the category.
Here’s what the survivors share — and it has almost nothing to do with how famous the founders are.
Genuine founder involvement, not licensing. Selena Gomez didn’t just lend her name to Rare Beauty. She built the brand around her own experience with mental health and self-acceptance, donating 1% of all sales to the Rare Impact Fund for mental health services. Hailey Bieber developed Rhode’s formulations around her personal skincare routine and stayed visibly involved in every product decision and marketing campaign. Consumers can tell the difference between a celebrity who shows up for the photo shoot and one who shows up for the product meetings.
Product obsession over product volume. Rhode launched with ten products. Not forty. Not a full color cosmetics line across every category. Ten carefully formulated skincare items that did specific things well. Rare Beauty’s early lineup was similarly focused — the Soft Pinch Liquid Blush became a cultural phenomenon on its own, driving organic TikTok content that no paid campaign could replicate. Compare that to brands that launched with massive SKU counts, trying to fill every shelf position from day one.
Financial discipline. Rhode’s numbers are remarkable: a 34% EBITDA margin with only 11% marketing spend. The brand generated over $200 million in DTC sales before entering wholesale — a level of profitability that’s nearly unprecedented for a three-year-old beauty brand. Rare Beauty crossed $400 million in net sales and grew its consumer base by more than double in a single year. These aren’t venture-subsidized growth stories. They’re profitable businesses.
Community-first marketing. Rhode was the number-one skincare brand in Earned Media Value in 2024, with 367% year-over-year EMV growth. That means customers and influencers were talking about the brand organically — not because they were paid to, but because the products gave them something worth sharing. Rare Beauty built a mental health community that extended far beyond product reviews. Both brands understood that in 2026, marketing isn’t something you do to your audience. It’s something your audience does for you — if you give them a reason.
Is the Celebrity Beauty Model Broken?
Not exactly. But the old version of it — famous person plus venture capital plus Sephora distribution equals guaranteed success — is dead.
The data tells a split story. Five of the top ten beauty brands by influencer marketing impact in 2025 were still celebrity-founded, according to industry research. Kylie Cosmetics continues to generate around $400 million annually under Coty’s ownership, with the prestige division reporting 13% revenue growth in fiscal year 2024. Huda Beauty keeps growing. The category isn’t collapsing — it’s bifurcating.
On one side: brands where the celebrity is genuinely the chief product officer, the creative director, and the community builder. Where fame is the amplifier, not the foundation. These brands are thriving.
On the other side: brands where a famous name was bolted onto a standard beauty playbook, funded by investors who confused celebrity reach with consumer demand. These brands are the ones filing for bankruptcy, going dark on Instagram, and getting dropped by retailers.
The correction happening in 2026 isn’t killing celebrity beauty. It’s killing lazy celebrity beauty. And for consumers, that’s probably a good thing — the brands that survive this shakeout will be the ones that actually earned their shelf space.
What Founders Can Learn From the Beauty Bloodbath
You don’t need to be launching a lipstick line for these lessons to matter. The celebrity beauty collapse is a concentrated version of a pattern that plays out across every consumer category: the gap between attention and retention.
Getting people to notice your product is a marketing problem. Getting them to come back is a product problem. The failed celebrity brands solved the first and ignored the second. They optimized for launch-day buzz and neglected the repeat-purchase mechanics that actually build a business.
Three principles from the survivors translate to any founder building a consumer brand in 2026:
Your valuation needs to reflect your revenue, not your potential. Pat McGrath Labs was valued at $1 billion on $40 million in actual sales. That’s a 25x revenue multiple for a cosmetics company — territory usually reserved for high-growth SaaS businesses, not physical products with thin margins and high return rates. When the growth didn’t materialize, the capital structure became a prison. If your valuation is built on projections rather than performance, you’re not raising money — you’re taking on risk.
Distribution dependency is an existential risk. If one retailer or one parent company can kill your brand by changing strategy, you don’t have a business — you have a feature in someone else’s business. Flower Beauty had no direct-to-consumer operation. Gxve had no retail presence outside Sephora. Rhode, by contrast, built a $200 million DTC business before entering wholesale. When you own the customer relationship, you own your survival.
Community compounds. Awareness doesn’t. Celebrity awareness spikes at launch and decays immediately. Community engagement compounds over time. Rare Beauty’s mental health mission creates ongoing emotional connection. Rhode’s skincare-as-self-care positioning generates daily UGC content. Both brands built flywheels where customers become marketers. The brands that died had awareness without community — the most expensive and least durable position in consumer business.
The celebrity beauty reckoning of 2026 isn’t a cautionary tale about famous people starting companies. It’s a reminder that no amount of name recognition can substitute for the fundamentals: a product people actually want, a financial structure that can survive a bad quarter, and a community that sticks around after the launch party ends.
